From a clinical perspective, type 2 diabetes mellitus might also be regarded as a vascular disease, characterized by increased arterial stiffness. Empagliflozin is a selective sodium-glucose cotransporter 2 inhibitor shown to improve glycemic control after short- and long-term treatment.¹ In the EMPA-REG OUTCOME study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), a prospective randomized double-blind study in patients with type 2 diabetes mellitus with established cardiovascular disease, treatment with empagliflozin reduced the primary combined cardiovascular end point (3P-MACE [3-point major adverse cardiovascular event]), as well as secondary end points of hospitalization because of heart failure, cardiovascular morbidity, total mortality, and renal end points.² We tested the hypothesis that improvements of vascular function and stiffness are involved in the observed improved cardiovascular and renal outcomes with empagliflozin treatment.

In this investigator-initiated prospective, double-blind, randomized, placebo-controlled, crossover, interventional single-center trial, 76 female and male patients (18–75 years of age) with diagnosed type 2 diabetes mellitus were randomized to either empagliflozin 25 mg orally once daily or placebo for 6 weeks, followed by the second 6-week treatment with the other compound (crossover). In 64 patients, any antidiabetic agent was withdrawn 4 weeks before the baseline examination. We analyzed the effects …

从临床角度来看，2型糖尿病也可被视为血管疾病，其特征是动脉僵硬度增加。Empagliflozin是一种选择性的钠-葡萄糖共转运蛋白2抑制剂，在短期和长期治疗后均可改善血糖控制。¹在EMPA-REG结果研究（2型糖尿病患者的恩格列净治疗心血管事件事件试验）中，这是一项对已确诊患有心血管疾病的2型糖尿病患者进行的前瞻性随机双盲研究，使用恩帕格列净治疗可降低主要的合并心血管终点点（3P-MACE [3点严重不良心血管事件]），以及因心力衰竭，心血管疾病的发病率，总死亡率和肾脏终点而住院的次要终点。²我们检验了以下假设，即依帕格列净治疗改善了心血管和肾脏的结局，从而改善了血管功能和僵硬。

在这项由研究者发起的前瞻性，双盲，随机，安慰剂对照，交叉，干预性单中心试验中，将76例确诊为2型糖尿病的男女患者（18-75岁）随机分配至依帕格列净25每天一次口服安慰剂或安慰剂，持续6周，连续6周，然后再用另一种化合物治疗6周（交叉使用）。在64例患者中，在基线检查前4周停用了任何抗糖尿病药。我们分析了效果……